scholarly journals Dupilumab in adolescents with moderate‐to‐severe atopic dermatitis: a 32‐week real‐world experience during the COVID‐19 pandemic

2021 ◽  
Author(s):  
K. Hansel ◽  
C. Patruno ◽  
E. Antonelli ◽  
G. Dal Bello ◽  
M. Napolitano ◽  
...  
Keyword(s):  
Atopic Dermatitis ◽  
Real World ◽  
Severe Atopic Dermatitis

scholarly journals Real‐world experience of dupilumab in the treatment of moderate‐to‐severe atopic dermatitis

2020 ◽  
Vol 59 (10) ◽  
Author(s):  
Nicole S. Kim ◽  
Khalad Maliyar ◽  
Luciana Oliveira ◽  
Ashley O’Toole ◽  
Melinda J. Gooderham
Keyword(s):  
Atopic Dermatitis ◽  
Real World ◽  
Severe Atopic Dermatitis

15260 Dupilumab treatment in adult patients with moderate to severe atopic dermatitis: A real-world single-center experience from Turkey

2020 ◽  
Vol 83 (6) ◽  
pp. AB144
Author(s):  
Andac Salman ◽  
Meryem Aktas ◽  
Esra Özkürkçü ◽  
Gonca Saraç ◽  
Oktay Taskapan ◽  
...  
Keyword(s):  
Atopic Dermatitis ◽  
Real World ◽  
Adult Patients ◽  
Severe Atopic Dermatitis ◽  
Single Center ◽  
Single Center Experience

Short-Term Evaluation of the Real-World Efficacy and Safety of Dupilumab for the Treatment of Moderate-to-Severe Atopic Dermatitis: A Canadian Multicenter Retrospective Cohort Study

2020 ◽  
Vol 24 (5) ◽  
pp. 468-473
Author(s):  
Christine E. Jo ◽  
Jorge R. Georgakopoulos ◽  
Matthew Ladda ◽  
Arvin Ighani ◽  
Asfandyar Mufti ◽  
...  
Keyword(s):  
Clinical Trials ◽  
Atopic Dermatitis ◽  
Clinical Practice ◽  
Real World ◽  
Treatment Options ◽  
The United States ◽  
Severe Atopic Dermatitis ◽  
Efficacy And Safety ◽  
Long Term Treatment ◽  
Tertiary Hospitals

Background Systemic therapy for atopic dermatitis (AD) has been challenging with limited safe and efficacious long-term treatment options. In 2017, dupilumab was approved in the United States, Europe, and Canada as the first targeted therapy for patients with moderate-to-severe AD. Despite promising efficacy and safety results in clinical trials, our understanding of dupilumab in clinical practice remains limited with few studies outside clinical trials in literature. Objective The aim of this study is to evaluate the efficacy and safety of dupilumab in clinical practice and discuss any differences in results between clinical trials and real-world results. Methods A retrospective chart review was conducted of consecutive patients receiving dupilumab treatment at two tertiary hospitals in Toronto, Canada, between December 2017 and May 2019. The primary efficacy endpoint was measured by Investigator’s Global Assessment (IGA) score of 0/1 at 16 weeks and all adverse events (AEs) experienced by patients were recorded. Results Of the 93 patients included in the study, 51 (55%) reached IGA 0/1 and 38 (41%) experienced ≥1 AE. There were no severe AEs or discontinuation prior to 16 weeks due to an AE. Conclusions These findings suggest a higher IGA-based efficacy profile with no newly identified safety concerns in patients treated with dupilumab at two tertiary hospitals in Toronto, Canada, compared to those in randomized controlled trials.

scholarly journals A real-world study evaluating adeQUacy of Existing Systemic Treatments for patients with moderate-to-severe Atopic Dermatitis (QUEST-AD)

2019 ◽  
Vol 123 (4) ◽  
pp. 381-388.e2 ◽  
Author(s):  
Wenhui Wei ◽  
Eric Ghorayeb ◽  
Michael Andria ◽  
Valery Walker ◽  
James Schnitzer ◽  
...  
Keyword(s):  
Atopic Dermatitis ◽  
Real World ◽  
Severe Atopic Dermatitis ◽  
Systemic Treatments

scholarly journals Early Clinical Efficacy After Dupilumab Therapy for Adult Severe Atopic Dermatitis in a Real-World Setting

2021 ◽  
Vol 147 (2) ◽  
pp. AB28
Author(s):  
Paloma Poza Guedes ◽  
Ruperto Gonzalez Perez ◽  
Elena Mederos Luis ◽  
Victor Matheu ◽  
Cristina Alava ◽  
...  
Keyword(s):  
Atopic Dermatitis ◽  
Clinical Efficacy ◽  
Real World ◽  
Severe Atopic Dermatitis ◽  
Real World Setting
Sign in / Sign up

Export Citation Format

Share Document